On April 23, 2025, Gubin Alexsandr, Gubina Liudmila, Zeynalova Pervin, and others from MedTeh Ltd., one of the largest distributors in Russia, visited SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD for an exchange and inspection. Dr. Yu Lei, founder and chairman of UNICAR-THERAPY, along with Wang Wei, Director of Quality, Dr. Xu Nan, Director of R&D, and other core executives of the company attended the reception and symposium. The purpose of this visit was to comprehensively understand the product technology capabilities of UNICAR-THERAPY, with a particular focus on its outstanding expertise in lentiviral vector production, deepen cooperation between both parties, and jointly explore broader development opportunities.During this visit, Gubin Alexsandr and his team toured the GMP production workshop of SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD. The workshop strictly adheres to cGMP standards, and the production processes for plasmids, lentiviral vectors, and CAR-T cells follow high standards and standardization. Subsequently, Gubin Alexsandr and his team conducted a detailed review of the relevant documents for the engineering systems and production facilities. After an in-depth tour and understanding, the MedTeh Ltd. team highly recognized UNICAR-THERAPY's innovative R&D capabilities, clinical transformation abilities, production plant facilities, quality management system, and documentation system. It was particularly noted that UNICAR-THERAPY’s lentiviral vector preparation platform addresses the industry pain point of limited lentiviral vector production capacity, showcasing strong technical advantages and innovation capabilities.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Currently, MedTeh Ltd. and SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD have reached a preliminary strategic cooperation agreement. Both parties will work together to promote the widespread application of CAR-T technology in the global cancer treatment field. SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD will always take "benefiting society and patients" as its mission and is committed to achieving the goal of "making cancer no longer an incurable disease." In the future, SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD will continue to focus on technological innovation, strengthen exchanges and cooperation with global partners, and contribute more to the advancement of the global cancer treatment cause.
About UNICAR-THERAPY
SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD ("UNICAR-therapy" for short) is a leading biopharmaceutical company dedicated to cutting-edge cell therapy technology innovation and transformation. It owns several original core technology platforms, including the SMART small nucleotide gene regulation empowerment technology platform, MADDS antibody innovative drugability technology platform, and 6H production quality control platform. Currently, the company has established a billion-level gene and cell therapy research and industry center in the North Shanghai Biomedical Park, creating an internationally first-class immunotherapy tumor innovation technology transformation center and an advanced, high-end genetically engineered immune cell industrial chain center. UNICAR-therapy has successfully collaborated with many well-known medical institutions at home and abroad, treating over a thousand patients with advanced cancer. UNICAR-therapy boasts a rich product pipeline, including autologous CAR-T technology, universal CAR-T technology, and in vivo CAR technology, with indications covering hematological tumors, solid tumors, and autoimmune diseases. Currently, three first-in-class/first-in-safety products are in the registration clinical research stage. ssCART-19 injection can be used as a breakthrough treatment for CAR-T contraindication central nervous system leukemia (commonly known as "brain white"), having obtained FDA orphan drug designation and being included in the NMPA breakthrough therapy list, now entering the critical clinical stage; U16 injection is a non-CD19 target lymphoma treatment product with significant efficacy, currently in Phase I clinical stage; U87 injection is a fully human CAR-T product, with proposed indications covering various malignant tumors such as lung cancer, triple-negative breast cancer, pancreatic cancer, nasopharyngeal cancer, and colorectal cancer, currently in Phase I of registration clinical trials.
